FDA Approves First Weekly Insulin for Children with Type 2 Diabetes
The FDA has expanded approval for insulin icodec, making it the first once-weekly insulin approved for children aged 10 and older with type 2 diabetes. The decision follows growing use of GLP-1 drugs among Medicare patients and rising interest in new treatments. Meanwhile, U.S. fertility rates hit a record low in 2025.
The U.S. Food and Drug Administration (FDA) has expanded approval for insulin icodec (Awiqli), marking the first time a once-weekly insulin is authorized for children aged 10 and older with type 2 diabetes. This decision, announced in October 2026, represents a significant shift in pediatric diabetes care by reducing treatment frequency from daily injections to just one per week. The approval follows growing clinical interest in long-acting insulin formulations and aligns with broader trends in diabetes management, including the rising use of GLP-1 receptor agonists—drugs like those developed by Eli Lilly and Novo Nordisk that have seen a 16-fold increase in Medicare use from 2010 to 2022. The American Diabetes Association (ADA) has also updated its guidelines to encourage earlier adoption of SGLT2 inhibitors and GLP-1 agonists, reflecting evolving standards of care. Novo Nordisk, a major player in the diabetes drug market, attempted to block Eli Lilly from advertising its drugs as more effective, but a U.S. judge denied that request, underscoring ongoing competition in the space. The approval of insulin icodec may influence prescribing patterns among pediatric endocrinologists and could affect patient adherence due to reduced injection burden. However, long-term safety data in children remains limited, and real-world effectiveness beyond clinical trials is still unknown.
This approval could ease treatment burdens for children with type 2 diabetes and their families, potentially improving quality of life and adherence rates. Given the rising prevalence of pediatric type 2 diabetes linked to obesity and lifestyle factors, a weekly insulin may help bridge gaps in access and consistency, especially in underserved communities. The broader market for diabetes therapeutics may see increased competition as companies develop longer-acting formulations, possibly accelerating innovation in delivery systems. Comparable to the introduction of once-weekly GLP-1 drugs for adults, this could signal a shift toward less frequent dosing across chronic disease management. However, cost and insurance coverage remain unresolved concerns—especially since insulin icodec is likely to be expensive, as past long-acting therapies have been. The impact on pediatric healthcare systems, particularly in schools and clinics with limited resources, may depend on reimbursement policies.